Search
Enkay Therapeutics Secures Nearly 100 Million Yuan in Funding to Bolster NK Cell Therapy Development
2 week ago /
Read about 0 minute
Author：小编
Enkay Therapeutics has recently concluded a successful A+++ funding round, securing approximately 100 million yuan from investors including Pudong Venture Capital and Xingbo Shenghui. This influx of capital will be pivotal in propelling the clinical trials of its core products forward and fostering the expansion of its novel drug pipeline, thereby expediting the clinical translation of NK cell-based therapies. Enkay Therapeutics is dedicated to the research and development of innovative NK cell-based drugs, with the ultimate goal of offering patients access to superior immunotherapy options. This latest round of funding will enable the company to sustain its technological advancements and refine its product portfolio.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
